Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

BSH 2019 | Daunorubicin and cytarabine approved for AML treatment within NHS Scotland

Zack Pemberton-Whiteley • 1 Apr 2019
BSH 2019
Acute Myeloid Leukemia Leukemia Cytarabine Daunorubicin

Daunorubicin and cytarabine were both recently approved by SMC for the treatment of AML within NHS Scotland. Zack Pemberton-Whiteley, Leukaemia Care, Worcester, UK, discusses this at the British Society for Haematology (BSH) 2019 Annual Meeting, held in Glasgow, UK.

More from Zack Pemberton-Whiteley

5:21
The effect of COVID-19 on CLL patient experiences
Zack Pemberton-Whiteley • 10 Sep 2021
4:16
Improving patient communication in CLL
Zack Pemberton-Whiteley • 10 Sep 2021
0:43
Health technology assessments
Zack Pemberton-Whiteley • 15 Jun 2019
0:34
HARMONY project: an overview
Zack Pemberton-Whiteley • 15 Jun 2019

Related Videos

4:21
ASH 2017 update on progress with novel AML treatments at MD Anderson
Naval Daver • 9 Dec 2017
1:28
FLT3 inhibitors for treating AML
Amir Fathi • 27 Sep 2018
2:30
Is low-dose cytarabine being overlooked in combination therapies for elderly AML?
Jorge Cortes • 5 Mar 2018
2:35
Stapled peptide ALRN-6924 for AML and MDS
David Sallman • 17 Dec 2018
The content of VJHemOnc is intended for healthcare professionals